ASPIRE Workshop 5: Application of Biostatistics

Slides:



Advertisements
Similar presentations
How would you explain the smoking paradox. Smokers fair better after an infarction in hospital than non-smokers. This apparently disagrees with the view.
Advertisements

Departments of Medicine and Biostatistics
1 Case-Control Study Design Two groups are selected, one of people with the disease (cases), and the other of people with the same general characteristics.
Biostatistics - Concepts Tudor Calinici – JPEMS 2014.
Inappropriate clopidogrel adherence explains stent related adverse outcomes Leonardo Tamariz, MD, MPH University of Miami.
1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.
BIOST 536 Lecture 3 1 Lecture 3 – Overview of study designs Prospective/retrospective  Prospective cohort study: Subjects followed; data collection in.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
RACIAL DISPARITIES IN PRESCRIPTION DRUG UTILIZATION AN ANALYSIS OF BETA-BLOCKER AND STATIN USE FOLLOWING HOSPITALIZATION FOR ACUTE MYOCARDIAL INFARCTION.
Multiple Choice Questions for discussion
Biostatistics Breakdown Common Statistical tests Special thanks to: Christyn Mullen, Pharm.D. Clinical Pharmacy Specialist John Peter Smith Hospital 1.
INFORMATION NOT RELEASABLE TO THE PUBLIC UNLESS AUTHORIZED BY LAW: This information has not been publicly disclosed and may be privileged and confidential.
Epidemiology The Basics Only… Adapted with permission from a class presentation developed by Dr. Charles Lynch – University of Iowa, Iowa City.
Tips for Researchers on Completing the Data Analysis Section of the IRB Application Don Allensworth-Davies, MSc Statistical Manager, Data Coordinating.
Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients Dr. Mya Thandar.
Age appears to be a significant effect modifier of the impact of palivizumab on RSV hospitalization risk. Given the rapid decrease of RSV risk with increasing.
MBP1010 – Lecture 8: March 1, Odds Ratio/Relative Risk Logistic Regression Survival Analysis Reading: papers on OR and survival analysis (Resources)
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
How do low-income limited English proficient adults use ambulatory health services when they have health insurance and access to interpreters? Elinor A.
1 Lecture 6: Descriptive follow-up studies Natural history of disease and prognosis Survival analysis: Kaplan-Meier survival curves Cox proportional hazards.
ASPIRE Workshop 4: Study Procedures and Data Elements, Sources, Uses, and Issues Kari L Olson, BSc(Pharm), Pharm D, FCCP, BCPS.
Pharmacy in Public Health: Epidemiology Course, date, etc. info.
Measures of disease frequency Simon Thornley. Measures of Effect and Disease Frequency Aims – To define and describe the uses of common epidemiological.
Children’s Outcomes Research Program The Children’s Hospital Aurora, CO Children’s Outcomes Research Program The Children’s Hospital Aurora, CO Colorado.
Dr John Cox Diabetes in Primary Care Conference Cork
ScWk 298 Quantitative Review Session
Case 66 year old male with PMH of HTN, DM, ESRD on renal replacement TIW, stroke in 2011 with right side residual weakness, atrial fibrillation, currently.
March 28 Analyses of binary outcomes 2 x 2 tables
1University of Kentucky, Lexington, Kentucky
ASPIRE Workshop 3: Choosing Your Study Design and Population
ASPIRE Session 3: Study Procedures and Data Elements, Sources, Uses, and Issues Thomas Delate, PhD, MS.
ASPIRE Class 4 Study Procedures and Data Elements, Sources, Uses, and Issues Thomas Delate, PhD, MS Clinical Pharmacy Research Scientist.
John Weeks1, MD Candidate 2017, Justin Hickman1, MD Candidate 2017
Present: Disease Past: Exposure
Date:2017/10/03 Presenter: Wen-Ching Lan
Journal Club Notes.
Epidemiological Studies
Biostatistics Case Studies 2016
Impact of State Reporting Laws on Central Line– Associated Bloodstream Infection Rates in U.S. Adult Intensive Care Units Hangsheng Liu, Carolyn T. A.
Women returning from Operation Iraqi Freedom/Operation Enduring Freedom: Comparison of Healthcare Utilization among Women & Men Veterans Mona Duggal MD.
Measurement Wu Gong, MS, MD
ASPIRE Class 5 Biostatistics and Data Collection Tools
ASPIRE Workshop 4: Study Procedures and Data Elements, Sources, Uses, and Issues Thomas Delate, PhD, MS.
Acute Urinary Retention During Pregnancy
ASPIRE Workshop 5: Application of Biostatistics
Some Epidemiological Studies
Lecture 1: Fundamentals of epidemiologic study design and analysis
ASPIRE Workshop 1: Conceiving the Research Idea
Medical Statistics Dr. Gholamreza Khalili
Jeffrey E. Korte, PhD BMTRY 747: Foundations of Epidemiology II
S1316 analysis details Garnet Anderson Katie Arnold
11/20/2018 Study Types.
NURS 790: Methods for Research and Evidence Based Practice
Common Problems in Writing Statistical Plan of Clinical Trial Protocol
Risk ratios 12/6/ : Risk Ratios 12/6/2018 Risk ratios StatPrimer.
Annals of Internal Medicine • Vol. 167 No. 12 • 19 December 2017
Risk adjustment using administrative and clinical data: model comparison
ASPIRE Workshop 1: Conceiving the Research Idea
Narrative Reviews Limitations: Subjectivity inherent:
Candice Preslaski, PharmD, BCPS, BCCCP
Critical Appraisal วิจารณญาณ
Interpreting Epidemiologic Results.
EPIDEMIOLOGY AS A TOOL TO EVALUATE QUALITY OF CARE
Patient engagement with digital therapeutic leads to reduction of A1C and costs in T2DM patients: Cost savings are correlated to both A1C drops as well.
ASPIRE Workshop 2: Choosing Your Study Design and Population
ASPIRE Workshop 5: Application of Biostatistics
Research Techniques Made Simple: Interpreting Measures of Association in Clinical Research Michelle Roberts PhD,1,2 Sepideh Ashrafzadeh,1,2 Maryam Asgari.
Global PaedSurg Research Training Fellowship
Introduction to epidemiology
Food Insecurity and Healthcare Expenditures
Presentation transcript:

ASPIRE Workshop 5: Application of Biostatistics Thomas Delate, PhD, MS Clinical Pharmacy Research Scientist Kaiser Permanente Colorado

What to Expect Today Review biostatisic principles Hands on application Questions related to your research project | © 2011 Kaiser Foundation Health Plan, Inc. For internal use only.

Example Study: Statin Letter Intervention Among patients with DM eligible for statin therapy, does an intervention involving a letter, a pre-ordered statin prescription, and pharmacist counseling increase statin initiation compared to no intervention (i.e., usual care)? Primary Objective: Compare statin-start rate (i.e., purchase of a statin Rx within 3 months after mailing date) between groups. How do you decide which statistical test should be used to test this objective?

Statin Letter Intervention What is a rate? What type of data are rates? Based on the study design (i.e., quasi-experimental, two groups), what potential bias/confounding variables need to be considered? What statistical test will you use?

Statin Letter Intervention What is a rate? Rate = The proportion of a population that experiences an outcome in a specified period of time. What type of data are rates? Percentages (yes/no experienced the outcome) so are binomial data. Based on the study design what potential bias/confounding variables need to be considered? Selection bias: Patients in the intervention clinic are more engaged in health behaviors. Confounding: Patients in the intervention clinic are older & sicker.

Statin Letter Intervention What statistical test will you use? To assess differences in rates between two groups: Chi-square test of association since outcome is binary (yes/no started a statin) and these are large groups To adjust for any potential selection bias: stratification on presence/non-presence of biasing factor To adjust for any potential confounding: logistic regression since outcome is binary (yes/no started a statin)

Statin Letter Intervention Secondary Objectives: Between the intervention and control groups Compare statin persistence rate (i.e., statin purchase 1 year after mailing date +/- 45 days) between groups Compare abnormal CK (>600) or ALT (>200) rate (i.e., at least one abnormal lab result within 6 months after mailing date) between groups What statistical tests will you use for these secondary objectives?

Statin Letter Intervention What statistical tests will you use for these secondary objectives? Persistence is a binary outcome (yes/no persistent with a statin) and these are large groups so chi-square test of association Abnormal CK is a binary outcome (yes/no) but the rate of these are low (i.e., a rare outcome) so Fisher’s exact test is likely appropriate

Purpose: To assess the relationship between A1c% and percent time in therapeutic INR range (TTR) for patients with diabetes receiving warfarin A1c% are normally distributed interval level data TTR are skewed interval level data Study Design: Retrospective cohort What statistical test will you use to quantify the relationship? What statistical test will you use if A1c% is categorized as >=8% & <8%?

A good way to develop a plan for statistical analysis is to think about what your Subject/Patient Characteristic table is likely to look like… Which variables do you think should be adjusted for in logistic regression modeling of the relationship between A1c<8% & TTR?

This is a logistic regression model of A1c>=8%. Which of the variables in the table appear to be associated with having an A1C value ≥8%? How would you interpret the odds ratio associated with ‘Age in Years’?

Study Design: Randomized controlled trial Purpose: To evaluate the utility of preemptive warfarin dose adjustment for preventing non-therapeutic INR following doxycycline+warfarin co-administration Primary outcome: Proportion of subjects with an INR increase ≥1 point over INR goal range upper limit Study Design: Randomized controlled trial Results: Primary outcome was reached in 0/21 intervention group subjects and 2/18 control group subjects (p = 0.201) What statistical test was used to generate the above p-value? Interpret this finding using layman’s terms Is there a need for regression analysis?

With only 37 patients, is it possible that this study was underpowered to detect a difference in the % of subjects with a ‘Below Range’ follow up INR?

Purpose: To assess the impact of an MTM program on mortality, healthcare utilization, and prescription medication costs and to quantify drug-related problems (DRPs) identified during MTM Study Design: Retrospective cohort with patents who were targeted for MTM but did and did not consent to receiving MTM Outcomes: All-cause death (binomial, primary outcome), hospitalization (binomial), and emergency department visit (binomial) rates and medication costs (ratio) in the 180 days following MTM targeting

Do you think the outcome ‘Pre-period Medication Cost’ is normally distributed? What statistical test should be used to compare this variable between groups?

What type of statistical test was used to generate this table? Why was it necessary to do an adjusted analysis? For which variable did the adjusted analysis make a difference in the outcome? Interpret the finding related to death in layman’s terms

Primary outcome: Colchicine exposure Purpose: To quantify the association of colchicine therapy with myotoxicity and blood dyscrasias in a cohort of insured patients Primary outcome: Colchicine exposure What would be the true outcome? What study design would be best for accomplishing the purpose of this study?

September 17, 2018 | © 2011 Kaiser Foundation Health Plan, Inc. For internal use only.

The odds ratio (OR) for exposure to colchicine for cases was 17 The odds ratio (OR) for exposure to colchicine for cases was 17.7 (95% confidence interval [CI] 2.4 to 128.2) When the analysis was limited to patients with diagnosis of gout the OR was 4.6 (95% CI 1.2 to 16.3) Which of these OR’s is more precise? Interpret these OR’s using layman’s terms

Questions regarding your studies?